Infections
233 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: Adenoviridae Infections 1, Asymptomatic Infections 5, Caliciviridae Infections 3, Chagas Disease 4, Chickenpox 8, Chikungunya Fever 1, Cholera 1, Clostridium Infections 39, Communicable Diseases 18, Coronavirus Infections 10, Cytomegalovirus Infections 4, Dengue 1, Diphtheria 11, Epstein-Barr Virus Infections 1, Escherichia coli Infections 4, Gonorrhea 6, Haemophilus Infections 2, Hemorrhagic Fever, Ebola 6, Herpes Genitalis 3, Herpes Zoster 12, Histoplasmosis 1, Influenza in Birds 1, Latent Tuberculosis 3, Leprosy, Multibacillary 3, Leptospirosis 2, Lyme Disease 1, Malaria 37, Malaria, Falciparum 16, Malaria, Vivax 9, Meningococcal Infections 1, Mycoses 4, Opportunistic Infections 1, Papillomavirus Infections 6, Parasitemia 1, Pneumococcal Infections 5, Rabies 3, Respiratory Syncytial Virus Infections 8, Rotavirus Infections 2, Sepsis 9, Sexually Transmitted Diseases 16, Shock, Septic 5, Staphylococcal Infections 1, Surgical Wound Infection 3, Tetanus 11, Treponemal Infections 1, Trypanosomiasis 6, Trypanosomiasis, African 1, Tuberculosis 13, Tuberculosis, Lymph Node 1, Tuberculosis, Multidrug-Resistant 3, Typhoid Fever 1, Virus Diseases 73, Zika Virus Infection 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| "Synchronised" arm (intervention) for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 4,4',4''-(4-PROPYL-(1H)-PYRAZOLE-1,3,5-TRIYL)TRISPHENOL for leptospirosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 4CMenB vaccine for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| 9vHPV Vaccine for papillomavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo + Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acoziborole for trypanosomiasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acoziborole for trypanosomiasis, african | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amoxicillin for treponemal infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ansuvimab for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artemether + Lumefantrine for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artemether + Lumefantrine + TAFENOQUINE for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| artemether-lumefantrine for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| artemether-lumefantrine + Mosquirixs for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artesunate for cytomegalovirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atovaquone-Proguanil for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atovaquone-Proguanil for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake timed prone and repositioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7760 for sepsis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7760 for staphylococcal infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bacillus calmette-guerin live antigen, unspecified substrain for tuberculosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bedaquiline for tuberculosis, multidrug-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benznidazole for chagas disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezlotoxumab for clostridium infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blmz for tuberculosis, multidrug-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood and adrenaline for cholera | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood and adrenaline for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BPaLMZ Regimen for latent tuberculosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabamiquine for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chlorhexidine for infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| coadministration for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Coartem® Baby for malaria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for haemophilus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®: DTaP for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®: DTaP for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin + Piperaquine tetraphosphate for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin + Piperaquine tetraphosphate + TAFENOQUINE for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin-Piperaquine (DP) for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for diphtheria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for tetanus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dolutegravir + Isoniazid + RIFAPENTINE for latent tuberculosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV and ActHIB® for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV and ActHIB® for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV combined vaccine for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV combined vaccine for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efineptakin alfa for opportunistic infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EG-MCV4 for meningococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ervebo® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etofenprox-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Factory-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal bacteriotherapy (FBT) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbial Transplantation for clostridium infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Fecal Microbiota Transplant for clostridium infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Fecal Microbiota Transplant (FMT) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota transplant (Promicrobioma) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation (FMT) for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation (FMT) + ISOTONIC SODIUM CHLORIDE SOLUTION for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota transplantion (FMT) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Transplant for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Virome Transplantation for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fidaxomicin for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flucytosine (5FC) for mycoses | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flucytosine (5FC) + Liposomal Amphotericin B (LAmB) for mycoses | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluvoxamine for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fmt for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| FMT (Fecal Microbiota Transplantation) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FMT-c Lactobacillus for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation B for pneumococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation C for pneumococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation D for pneumococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fosravuconazole + benznidazole for chagas disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fresh FMT for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Frozen-and-Thawed FMT for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gepotidacin for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| GSK malaria vaccine 257049 Vaccine for malaria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Healthy donor stool for clostridium infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hemoperfusion for leptospirosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hydroxychloroquine + azithromycin for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for adenoviridae infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Immulina for virus diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inmazeb for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Isoniazid + RIFAPENTINE for latent tuberculosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ivermectin for asymptomatic infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivermectin for communicable diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivermectin for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Landiolol for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for cytomegalovirus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for epstein-barr virus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 0.01x IV Dose for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 0.1 x IV dose for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 IV Infusion Dose for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liposomal Amphotericin B (LAmB) for mycoses | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Dose FMT Capsule DE for clostridium infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 200 mg + PYRONARIDINE for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 200 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 330 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 500 mg + M5717 660 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 60 mg + PYRONARIDINE for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 60 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 660mg + PYRONARIDINE for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 660mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine for tuberculosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Malaria Vaccine 257049 for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Malaria Vaccine 257049 + Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matrix-M with RH5.2 VLP and/or R21 for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MBK-01 for clostridium infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Meningococcal Group B Vaccine for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin for tuberculosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylenblue for malaria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| METRONIDAZOLE + Vancomycin + Loperamide + FECAL MICROBIOTA for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midodrine for sepsis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mosquirixs for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moxifloxacin + rifapentine for tuberculosis, lymph node | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-1018-H5 for influenza in birds | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mtbvac for tuberculosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N-Acetylcysteine (NAC) Treatment for tuberculosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nifurtimox for chagas disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Nirsevimab for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (3 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for haemophilus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for pneumococcal infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Penn Microbiome Therapy - 001 for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Penn Microbiome Therapy - 001 + Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pentacel®: DTaP-IPV/Hib combined for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pentacel®: DTaP-IPV/Hib combined for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Permethrin-treated lesu for malaria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Permethrin-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PG4 for pneumococcal infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for tuberculosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Posaconazole for chagas disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Povidone-iodine for surgical wound infection | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Primaquine for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Prone Position for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| prone positioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pvs230D1-EPA/Matrix-M for malaria, vivax | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pvs230D1-EPA/Matrix-M for parasitemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Quabodepistat for tuberculosis, multidrug-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21 in Matrix- M adjuvant vaccine for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21/Matrix-M - single vial formulation for malaria | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21/Matrix-M - two vial formulation for malaria | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rabies vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RBX2660 for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RBX2660 for communicable diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RBX2660 (microbiota suspension) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for herpes zoster | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RSVPreF3 OA investigational vaccine for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S-337395 for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Single high dose of liposomal amphotericin B for histoplasmosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Soaked lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standardized kudzu for sexually transmitted diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sucrose for surgical wound infection | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tafenoquine for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Tafenoquine + chloroquine for malaria, vivax | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tafenoquine succinate for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telacebec + Rifampicine for leprosy, multibacillary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telacebec 300 mg for leprosy, multibacillary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telacebec 600 mg for leprosy, multibacillary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) for gonorrhea | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml) for gonorrhea | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tetanus-Diphtheria booster for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Titrated weaning of vasopressin. for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Topical ceftazidime and vancomycin for surgical wound infection | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tradipitant for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for sepsis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 high-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 low-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valganciclovir for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vancomycin for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vasopressin for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Venous Excess Ultrasound (VEXUS)-Guided Management for shock, septic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vi-Typhoid Conjugate Vaccine (Vi-TCV) for typhoid fever | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viral Specific T-cells (VSTs) for virus diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VLA15 for lyme disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| VXA-G1.1-NN for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for coronavirus infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for chikungunya fever | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for dengue | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for zika virus infection | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zabdeno® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zelicapavir for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zoliflodacin for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.